Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988595 · ClinicalTrials.gov registry record · Phase 1
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer
A Phase 1 study of Hormone Receptor Positive Metastatic Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 10
- Study locations
NCT03988595: Active Phase 1 study of Hormone Receptor Positive Metastatic Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03988595 is a Phase 1 study of Hormone Receptor Positive Metastatic Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03988595, a Phase 1 study of Hormone Receptor Positive Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the growth of tumors.
Primary Outcome
Feasibility is defined in terms of the relative dose intensive (RDI), the proportion of the planned exercise prescription that was completed without requiring a dose modification or interruption. The MFD is defined as the dose estimated to result in approximately 70% of patients achieving an RDI ≥ 75%.
Conditions Studied
Interventions
- OTHER Exercise Treatment
Study Locations (10)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Health Systems (Montefiore Medical Center) (Data Collection Only) - The Bronx
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Indiana
- Indiana University (Data Collection Only) - Indianapolis
Maryland
- Johns Hopkins Hospital (Data Collection Only) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-06-12 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 1 |
What the registry record for NCT03988595 still lists
NCT03988595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Hormone Receptor Positive Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exercise Treatment is the first listed.
NCT03988595 lists 10 locations in 4 states (New York, New Jersey, Indiana).
Frequently Asked Questions
What is clinical trial NCT03988595 about?
NCT03988595 is a clinical study titled "Exercise Treatment With Standard Therapy for Metastatic Breast Cancer". This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the growth of tumors.
What is the current status of trial NCT03988595?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-06-12. Estimated completion is 2026-08-01.
What conditions does trial NCT03988595 study?
This clinical trial studies the following conditions: Hormone Receptor Positive Metastatic Breast Cancer.
What interventions are being tested in trial NCT03988595?
The interventions under investigation include: Exercise Treatment (OTHER).
Who is sponsoring clinical trial NCT03988595?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988595 being conducted?
This trial has 10 study locations across Indiana, Maryland, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03988595's enrollment target sits among peer trials
54 931st of 2000 higher than 1,053 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI